Clinical Trials Logo
  1. Home
  2. Antibody-mediated Rejection
  3. NCT02533596

Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange

Antibody-mediated Rejection Clinical Trial

Official title:
Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange

Clinical Trial Summary

Therapeutic plasma exchange (TPE) is an established treatment modality for the acute removal of pathophysiological relevant mediators in various diseases. Adipokines have recently been found to play an important role in a variety of immunologic diseases. However, in many of these disease states cardiac and inflammatory involvement is common and biomarkers are routinely used for diagnosis or assessment of therapeutic success. The effect of TPE on biomarkers used in the clinical routine has not been investigated. The aim of this study is to determine adipokine and cardiac biomarker removal during TPE therapy.

Clinical Trial Description

We performed a observational prospective single-centered study. Every patient received two consecutive therapeutic plasma exchange (TPE) sessions during the study. Plasma exchange therapy was performed using either the Spectra Optia® or the Octo Nova® apheresis system. Anticoagulation was applied either by heparin or citrate. The prescribed dose of exchange volume of every TPE treatment was 1.1-times the individual calculated total plasma volume, using the Nadler-Allen equation. A substitute fluid with 5% albumin concentration was used in every treatment. Blood samples for measurement of different adipokines (resistin, leptin, soluble ICAM-1, soluble CD40 ligand, monocyte chemoattractant protein-1 (MCP-1), soluble tumor necrosis factor receptor (sTNF-R) as well as cardiac and inflammatory biomarkers and routine chemistry were drawn before (pre-TPE) and at the end (post-TPE) of the first and second TPE session. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02533596
Study type Observational
Source Hannover Medical School
Contact
Status Completed
Phase N/A
Start date September 2010
Completion date March 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT04367610 - Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Completed NCT05021484 - Felzartamab in Late Antibody-Mediated Rejection Phase 2
Terminated NCT02120482 - Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study N/A
Active, not recruiting NCT03744910 - Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients Phase 3
Terminated NCT03221842 - Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients Phase 3
Terminated NCT01895127 - Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation Phase 2
Completed NCT02013037 - The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation Phase 3
Recruiting NCT03737136 - Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR N/A
Recruiting NCT05913596 - The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation N/A
Active, not recruiting NCT04541914 - Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT N/A
Withdrawn NCT03805178 - Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization Phase 2
Enrolling by invitation NCT05300451 - Daratumumab in Cardiac Allograft AMR & HLA Desensitization Prior to Transplantation Phase 2
Recruiting NCT06112951 - A Prospective Randomized Trial of ECP in Subclinical AMR N/A
Active, not recruiting NCT04897438 - Donor-derived Cell-free DNA for Early Diagnosis of Antibody-mediated Rejection N/A
Recruiting NCT05004493 - Biorepository and Registry for Plasma Exchange Patients
Completed NCT04026087 - Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation
Active, not recruiting NCT03994783 - Transplant Antibody-Mediated Rejection: Guiding Effective Treatments Phase 3
Not yet recruiting NCT05862766 - Isatuximab in Lung Transplant Recipients Early Phase 1
Recruiting NCT04368962 - DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients
Completed NCT03444103 - A Pilot Trial of Clazakizumab in Late ABMR Phase 2